Beth Israel Deaconess Medical Center
bidmc.orgLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
559
Active
107
Phase 3
21
Total enrollment
12,863,184
Pipeline matrix
Showing 40 of 45 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| liraglutide | — | — | — | — | — | 2 | |
| Nitrous oxide | — | — | — | — | — | 1 | |
| Lorcaserin HCl | — | — | — | — | — | 1 | |
| Infliximab | — | — | — | — | — | 1 | |
| Cabotegravir Injection [Apretude] | — | — | — | — | — | 1 | |
| administration of bupivacaine 7.5 mg and fentanyl 24 mcg every 40 minutes | — | — | — | — | — | 1 | |
| Tiagabine | — | — | — | — | — | 1 | |
| 0.25% Bupivacaine | — | — | — | — | — | 1 | |
| Sleep Hygiene, Brain Game, and IV Acetaminophen Intervention | — | — | — | — | — | 1 | |
| Control | — | — | — | — | — | 1 | |
| Statins | — | — | — | — | — | 1 | |
| Finasteride | — | — | — | — | 2 | ||
| Cyclophosphamide | — | — | — | — | — | 4 | |
| Cisplatin | — | — | — | — | — | 3 | |
| rituximab | — | — | — | — | — | 3 | |
| Doxorubicin | — | — | — | — | — | 2 | |
| Hydrocortisone | — | — | — | — | — | 2 | |
| Nivolumab | — | — | — | — | — | 2 | |
| Normal Saline 10 mL | — | — | — | — | — | 1 | |
| raloxifene | — | — | — | — | — | 1 | |
| Roflumilast 0.3% topical foam | — | — | — | — | — | 1 | |
| Fresh Frozen Plasma | — | — | — | — | — | 1 | |
| MVI and lactated ringers | — | — | — | — | — | 1 | |
| Epcoritamab | — | — | — | — | — | 1 | |
| Pleural Saline Irrigation | — | — | — | — | — | 1 | |
| DC/AML Fusion Vaccine | — | — | — | — | — | 1 | |
| Fulvestrant | — | — | — | — | — | 1 | |
| topical vaginal application lidocaine gel | — | — | — | — | — | 1 | |
| Dexrazoxane | — | — | — | — | — | 1 | |
| Dexrazoxane placebo | — | — | — | — | — | 1 | |
| Liposomal Doxorubicin | — | — | — | — | — | 1 | |
| Vincristine | — | — | — | — | — | 1 | |
| Prednisone | — | — | — | — | — | 1 | |
| Polatuzumab Vedotin | — | — | — | — | — | 1 | |
| Olaparib | — | — | — | — | — | 1 | |
| Gemcitabine | — | — | — | — | — | 1 | |
| Durvalumab | — | — | — | — | — | 1 | |
| Abrocitinib | — | — | — | — | — | 1 | |
| DC/AML fusion cells | — | — | — | — | — | 1 | |
| Aspirin | — | — | — | — | 4 |
5 more active programs hidden
Next readouts
- 2023-09-30
- 2025-03
- 2025-07-30
- 2025-08-31
- 2025-09-18
- 2025-12-30
- 2026-03-27
- 2026-03-31
- 2026-05-01
- 2026-06-30
Top conditions
- Breast Cancer23
- Obesity17
- Schizophrenia12
- Healthy9
- Prostate Cancer9
- Ovarian Cancer8
- Septic Shock8
- Respiratory Failure8
Frequently asked questions about Beth Israel Deaconess Medical Center
- How many clinical trials does Beth Israel Deaconess Medical Center have on ClinicalTrials.gov?
- Beth Israel Deaconess Medical Center is listed as the lead sponsor on 559 clinical trials in ClinicalTrials.gov, 107 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Beth Israel Deaconess Medical Center's trials are in Phase 3?
- 21 of Beth Israel Deaconess Medical Center's trials are in Phase 3, spread across 45 active drug programs.
- What therapeutic areas does Beth Israel Deaconess Medical Center focus on?
- Beth Israel Deaconess Medical Center's most-studied conditions on ClinicalTrials.gov are Breast Cancer, Obesity, Schizophrenia, Healthy, Prostate Cancer.
- When are Beth Israel Deaconess Medical Center's next clinical trial readouts?
- Beth Israel Deaconess Medical Center has 10 upcoming primary-completion readouts tracked here; the soonest is “Nivolumab in Patients With High-Risk Biochemically Recurrent Prostate Cancer”, expected around 2023-09-30.